Avita Medical Gets Premarket Approval for New Version of its Recell Device

February 23, 2022

Avita Medical has received a supplemental premarket approval from the FDA for the newest version of its Recell autologous cell-harvesting device.

The system, which is intended to treat acute thermal burns, enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient’s own skin.

The new version of the device has been modified to reduce setup steps by approximately one-third and to enable its use with fewer support personnel, the company said.

Avita plans to start marketing the Recell system in the U.S. in the second quarter of 2022.

View today's stories